📰 Eric Soyer News
Eric Soyer News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Eric Soyer. Real-time updates on events, politics, business and more.
March 11, 2024
Lyon and Cambridge , March 11, 2024, at 07:00am CET – PHAXIAM Therapeutics , a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today...
February 21, 2024
Phaxiam Therapeutics says it has notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares representing its ordinary shares, which should be effective...
February 20, 2024
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital MarketPHAXIAM remains listed on Eu...
February 20, 2024
Investegate announcements from PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
November 14, 2023
Investegate announcements from PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023
October 24, 2023
Investegate announcements from PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus
October 11, 2023
PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains Data from PHAXIAMs phagogram, first...
October 9, 2023
PHAXIAM Therapeutics announces high coverage performanceof its two anti-Staphylococcus aureus phages over clinical strains Data from PHAXIAM’s phagogram, first CE-marked Phage Susceptibility Test ,...
October 9, 2023
PHAXIAM Therapeutics announces high coverage performanceof its two anti-Staphylococcus aureus phages over clinical strains Data from PHAXIAM’s phagogram, first CE-marked Phage Susceptibility Test (PST), showed 98% response rate over 105 clinical S. aureus strains Lyon (France) et Cambridge (MA, US), October 9, 2023 at 10:05pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announced a very high spectrum of activity of its anti-S. aureus (PP1493 and PP1815) phages ...
October 5, 2023
04.10.2023 - PHAXIAM Receives Compliance Notice from Nasdaq Lyon (France) et Cambridge (MA, US), October 4, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announced that it has received confirmation from Nasdaq that it has ...